ALK-IN-1

Cat. No.: HY-13464

CAS No.: 1197958-12-5

Molecular Formula: $C_{26}H_{34}ClN_6O_2P$

Molecular Weight: 529.01

Target: Anaplastic lymphoma kinase (ALK)

Pathway: Protein Tyrosine Kinase/RTK

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (94.52 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.8903 mL	9.4516 mL	18.9032 mL
	5 mM	0.3781 mL	1.8903 mL	3.7806 mL
	10 mM	0.1890 mL	0.9452 mL	1.8903 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (4.73 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (4.73 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (4.73 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

ALK-IN-1 (Brigatinib analog) is a highly efficient and selective inhibitor of ALK kinase, derived from patent US20140066406 A1.

CUSTOMER VALIDATION

- Harvard Medical School LINCS LIBRARY

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Sen Zhang, Frank Wang, Jeffrey Keats, Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066). Cancer Research: April 15, 2010; Volume 70, Issue 8, Supplement 1

[2]. Victor M. Rivera, Frank Wang, Rana Anjum, Abstract 1794: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC. Cancer Research: April 15, 2012; Volume 72, Issue 8, Supplement 1

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA